阿替普酶静脉溶栓治疗急性心肌梗死疗效观察

目的:观察阿替普酶静脉溶栓治疗急性心肌梗死疗效。方法:48例AMI患者给予阿替普酶静脉溶栓治疗,随机分为50mg组24例及100mg加速给药组24例,对比两组治疗前后冠脉再通率及并发症发生率。结果:48例患者静脉溶栓治疗成功37例,总再通率77%。其中,50mg组再通18例,再通率75%,出血3例,死亡1例,无效2例;100mg加速给药组再通19例,再通率79.1%,出血3例,死亡1例,无效1例。结论:阿替普酶静脉溶栓治疗急性心肌梗死疗效好,其中加速给药组更佳。

Objective ： observing the therapeutic effect of intravenous coronary thrombolysin alteplase for patients with AMI. Methods： We received and treated 48 patients with AMI from Jan. 2007 to Dec. 2010, dividing them into two groups randomly. Giving 24 patients in first group intravenous 50mg alteplase each, and 24 patients in the second group were given accelerated delivery 100mg aheplase each. After treatment, we compared the recanalization rate and complications occurring rate of the two groups. Results ：Total 48 patients accepted alteplase thrombolytic therapy. 37 succeeded. And the total recanalization rate is 77%. In the first group, 18 patients acquired recanalization, recanalization rate is 75%, 3 patients occurred bleeding, 1 patient dide, 2 patients invalided. In the second group, 19 patients acquired recanalization, recaralization rate is 79. 1% ,3 patients occurred bleeding, 1 patient died, 1 patient invalided. Conclusion： alteplase thromlolytic therapy has a good effect on curing AMI. And using accelerated clelivery alteplase group has better result. It is worth to being popularized in primary lev el hospitals.